Advertisement

Neuromyelitis optica testing and treatment: Availability and affordability in 60 countries

      Highlights

      • Physicians from 64 countries globally were surveyed on NMO care.
      • Aquaporin-4 and MOG antibodies were available in 68% and 38% of countries.
      • The average cost of an aquaporin-4 antibody test was 209 USD.
      • <10% of low-income countries’ patients are estimated to afford treatment.
      • The absence of antibody tests is a main barrier to NMO care in the developing world.

      Abstract

      Background

      We characterize the variations in availability and affordability of NMO diagnostic testing and treatment by geographic region and country-level income group.

      Methods

      A structured survey was distributed in English, French, and Spanish in late 2018 to neurologists and other physicians who encounter NMO patients.

      Results

      Respondents (response rate 45%, 64/143 countries contacted) came from all WHO world regions and World Bank country income levels (49% university-based; 13 low-, 16 lower middle-, 16 upper-middle-, and 15 high-income countries). The average cost of an aquaporin-4 antibody (AQP4-Ab) test to a patient globally was 209 USD, and the average cost of NMO treatment per year was 3,819 USD. AQP4-Ab and myelin oligodendrocyte glycoprotein-antibody (MOG-Ab) testing were available in 68% and 38% of all countries. Low-income countries had poor availability of both AQP4-Ab (2/13 countries) and MOG-Ab (1/13) compared to high-income countries (15/15 AQP4-Ab, 13/15 MOG-Ab). Nearly half (48%, 13/27) of African and Eastern Mediterranean countries had access to neither test.

      Global treatment availability and usage

      Azathioprine (88%), rituximab (50%), mycophenolate mofetil (57%), intravenous methylprednisolone (98%), oral prednisone (68%), plasma exchange (78%), intravenous immunoglobulin (72%). Whereas 70–100% of high-income countries’ patients could afford treatment without incurring a catastrophic health expenditure, <10% of low-income country patients could. Most low-income countries (12/13) reported the patient pays for NMO care entirely without public assistance

      Conclusions

      There is a gap in access to diagnostic testing for NMO in non-high-income countries, even in countries where acute and immunosuppressive treatment for NMO are available.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Asgari N.
        • Lillevang S.T.
        • Skejoe H.P.
        • Falah M.
        • Stenager E.
        • Kyvik K.O.
        A population-based study of neuromyelitis optica in Caucasians.
        Neurology. 2011; 76: 1589-1595
        • Assadeck H.
        • Toudou Daouda M.
        • Adehossi Omar E.
        • Mamadou Z.
        • Hassane Djibo F.
        • Douma Maiga D.
        Inflammatory demyelinatiung diseases of the central nervous system in Niger.
        Rev. Neurol. (Paris). 2019; 175: 261-268
        • Bhigjee A.I.
        • Moodley A.A.
        • Roos I.
        • Wells C.L.
        • Ramdial P.
        • Esser M.
        The neuromyelitis optica presentation and the aquaporin-4 antibody in HIV-seropositive and seronegative patients in KwaZulu-Natal, South Africa.
        South Afr. J. HIV Med. 2017; 18: 684
        • Cabrera-Gómez J.A.
        • Kurtzke J.F.
        • González-Quevedo A.
        • Lara-Rodríguez R.
        An epidemiological study of neuromyelitis optica in Cuba.
        J. Neurol. 2009; 256: 35-44
        • Collazo I.M.
        • Weinshenker B.
        • Nasr Z.
        • Lopez A.
        Long term mortality in neuromyelitis optica spectrum disorder (P6.414).
        Neurology. 2018; 90
        • Dinerstein C.
        Why is Soliris the Most Expensive Drug in the US?.
        American Council on Science and Health, 2017 ([Internet][Accessed March 7, 2019]. Available from:)
        • Etemadifar M.
        • Nasr Z.
        • Khalili B.
        • Taherioun M.
        • Vosoughi R.
        Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis.
        Mult. Scler. Int. 2015; 2015174720
        • Feigin V.L.
        • Abajobir A.A.
        • Abate K.H.
        • Abd-Allah F.
        • Abdulle A.M.
        • Abera S.F.
        • et al.
        Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.
        Lancet Neurol. 2017; 16: 877-897
        • Gaye N.M.
        • Fall M.
        • Diop A.M.
        Neuromyelitis optica spectrum disorders (NMO-SD) in a Sub-Saharan Africa country: a preliminary study of sixteen Senegalese cases.
        Mult. Scler. Relat. Disord. 2018; 27: 179-183
        • Harttgen K.
        • Vollmer S.
        United Nations Development Programme. Human Development Reports.
        2011 November (Research Paper 2011/13)
        • Johnson D.G.
        The functional distribution of income in the United States, 1850-1952.
        Rev. Econ. Stat. 1954; 36: 175-182
        • Kaldor N.
        Capital accumulation and economic growth.
        The Theory of Capital. Macmillan & Co Ltd, 1961
        • Mateen F.J.
        • Clark S.J.
        • Borzello M.
        • Kabore J.
        • Seidi O.
        Neurology training in sub-Saharan Africa: a survey of people in training from 19 countries.
        Ann. Neurol. 2016; 79: 871-881
        • McLane H.C.
        • Berkowitz A.L.
        • Patenaude B.N.
        • et al.
        Availability, accessibility, and affordability of neurodiagnostic tests in 37 countries.
        Neurology. 2015; 85: 1614-1622
        • Mealy M.A.
        • Kessler R.A.
        • Rimler Z.
        • et al.
        Mortality in neuromyelitis optica is strongly associated with African ancestry.
        Neurol. Neuroimmunol. Neuroinflamm. 2018; 5: e468
        • Pandit L.
        • Mustafa S.
        • Kunder R.
        • Shetty R.
        • Misri Z.
        • Pai S.
        Optimizing the management of neuromyelitis optica and spectrum disorders in resource poor settings: experience from the Mangalore demyelinating disease registry.
        Ann. Indian Acad. Neurol. 2013; 16: 572-576
        • Pittock S.J.
        • Lennon V.A.
        • McKeon A.
        • et al.
        Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
        Lancet Neurol. 2013; 12: 554-562
        • Ravallion M.
        • Chen S.
        • Sangraula P.
        Dollar a Day Revisited (Report).
        The World Bank, Washington DC2008
        • Solow R.M.
        Technical change and the aggregate production function.
        Rev. Econ. Stat. 1957; 39: 312
        • Stovner L.J.
        • Nichols E.
        • Steiner T.J.
        • Abd-Allah F.
        • Abdelalim A.
        • Al-Raddadi R.M.
        • et al.
        Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet Neurol. 2018; 17: 954-976
        • Trebst C.
        • Jarius S.
        • Berthele A.
        • et al.
        Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).
        J. Neurol. 2014; 261: 1-16
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • Wingerchuk D.M.
        • Banwell B.
        • Bennett J.L.
        • Cabre P.
        • Carroll W.
        • Chitnis T.
        • et al.
        International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
        Neurology. 2015; 85: 177-189
        • World Bank Data Team
        New Country Classifications by Income Level.
        The Data Blog, 2018 ([Internet][cited 2019 Jan 7]. Available from:)
        • Zunt J.R.
        • Kassebaum N.J.
        • Blake N.
        • Glennie L.
        • Wright C.
        • Nichols E.
        • et al.
        Global, regional, and national burden of meningitis, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
        Lancet Neurol. 2018; 17: 1061-1082